X4 Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview

X4 Pharmaceuticals

21/03/2025 13:01

X4 Pharmaceuticals Inc XFOR.OQ XFOR.O is expected to show a rise in quarterly revenue when it reports  results on March 25 for the period ending December 31 2024

The Boston Massachusetts-based  company is expected to report revenue of $1.041 million, according to the mean estimate from 6 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for X4 Pharmaceuticals Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $3.13‚Äč, above‚Äč its last closing price of $0.30. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.15
-0.17
-0.18
Missed
-4.1
Jun. 30 2024
0.13
0.01
-0.07
Missed
-1,325.9
Mar. 31 2024
-0.15
-0.16
-0.26
Missed
-59.6‚Äč
Dec. 31 2023
-0.17
-0.15
-0.10
Beat
34.6
‚Äč‚ÄčSep. 30 2023
-0.15
-0.15
-0.01
Beat
93.3
Jun. 30 2023
-0.16
-0.16
-0.33
Missed
-102‚Äč
Mar. 31 2023
-0.21
-0.22
-0.16
Beat
26.3
Dec. 31 2022
-0.21
-0.24
-0.29
Missed
-20.2

This summary was machine generated March 21 at 13:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)